Last Update 26 Jun 26
Fair value Decreased 28%RSSS: Cost Discipline And Healthier Revenue Mix Will Support Rebound
Analysts have trimmed their average price target on Research Solutions from about $5.33 to roughly $3.83, citing mixed quarterly results, softer revenue trends, churn challenges and updated assumptions for revenue growth, margins and future P/E, even as they also note improving cost controls and a healthier revenue mix.
Analyst Commentary
Recent commentary on Research Solutions reflects a mix of optimism about execution and cost discipline alongside concern about slower revenue and churn, which together have fed into lower price targets and a reset in valuation expectations.
Bullish Takeaways
- Bullish analysts highlight that, despite mixed quarterly results, the revenue mix at Research Solutions is moving in what they view as a healthier direction, which they see as supportive of longer term growth potential.
- Adjusted EBITDA performance is described as essentially in line with forecasts, supported by good cost controls. This suggests to these analysts that management is handling profitability and expense levels with discipline.
- Some analysts point to strong progress in winning new logos and upselling existing customers, which they see as evidence of solid underlying execution even with recent revenue softness.
- Even after reducing targets, bullish analysts maintain positive ratings, indicating they still see upside potential relative to the current stock valuation.
Bearish Takeaways
- Bearish analysts emphasize that Q3 revenues were below forecasts and that a recent quarter showed a 4% revenue decline from last year. They view this as a risk for near term growth expectations.
- Churn remains an ongoing issue for Research Solutions, raising questions about customer retention and the durability of recurring revenues in their models.
- The stock price has fallen by nearly 45% from its 52 week highs. Analysts see this as a signal that the market has become more cautious on the company’s growth and execution story.
- Lowered price targets and revised assumptions for revenue growth, margins and future P/E indicate that some analysts are resetting their outlook, reflecting a more conservative stance on valuation until trends improve.
What’s in the News for Research Solutions
- Research Solutions launched the Scite Claude Connector, integrating Scite's full text search, Smart Citations, and institutional holdings resolution directly into Anthropic's Claude for Scite subscribers on paid Claude plans. Source: Company product announcement
- The Scite Claude Connector allows Claude users to search more than 250 million scientific articles, see whether claims are supported, contrasted, or mentioned by the literature, and access full text via institutional holdings without leaving a Claude conversation. Source: Company product announcement
- The launch extends Scite's reach beyond its existing ChatGPT app, positioning Scite and Article Galaxy as an evidence and acquisition layer that can sit behind multiple AI assistants and custom research agents. Source: Company product announcement
- Research Solutions also introduced Article Galaxy MCP, which connects Article Galaxy's literature acquisition and rights management infrastructure to AI tools such as ChatGPT, Claude, Microsoft Copilot, Cursor, and other MCP compatible platforms. Source: Company product announcement
- Article Galaxy MCP supports end to end literature acquisition, AI rights management, compliant content delivery, admin controls, and flexible order management, with the goal of keeping researchers and AI agents inside their preferred AI environments while maintaining publisher licensing and compliance. Source: Company product announcement
Valuation Changes for Research Solutions
- Fair Value: The average analyst fair value estimate moved lower from $5.33 to $3.83 per share, a reduction of roughly 28%.
- Discount Rate: The discount rate used in analyst models eased slightly from 8.90% to about 8.76%.
- Revenue Growth: Assumed revenue growth in forecasts fell significantly from about 4.95% to roughly 1.45%.
- Net Profit Margin: The forecast profit margin was trimmed from about 17.64% to around 8.28%, implying a more conservative earnings profile for Research Solutions.
- Future P/E: The assumed future P/E multiple increased from about 23.4x to roughly 41.0x, indicating a higher valuation multiple being applied to those revised earnings assumptions.
Catalysts
About Research Solutions
Research Solutions provides SaaS and AI powered tools that help enterprises and academic institutions discover, license and use scientific content more efficiently and in a copyright compliant way.
What are the underlying business or industry changes driving this perspective?
- Growing enterprise demand to apply AI directly on proprietary and licensed research content, paired with the new RightsDel AI rights offering, is expected to support higher platform seat adoption, cross sells and recurring revenue and average selling prices over time.
- Publishers accelerating their shift to AI licensing and needing a scalable AI gateway creates a structural role for Scite and Article Galaxy as infrastructure partners, supporting ARR growth and expanding high margin revenue share streams.
- The emergence of AI specific usage metrics on top of traditional download based reporting positions the company as a standard setter for measuring AI driven research activity, which can underpin premium analytics tiers and support higher gross margins.
- Continued mix shift from lower margin transaction revenue to the 88 percent margin platforms business, enabled by B2B ARR wins and higher ASPs, is expected to expand blended gross margin and support growth in operating income and earnings.
- Improved B2C product velocity and the funnel of individual users converting into enterprise opportunities, with pipeline from this channel rising from fifty thousand dollars to over one million dollars year over year, can support logo growth and upsell driven ARR and ultimately support net margin expansion.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Research Solutions's revenue will grow by 1.5% annually over the next 3 years.
- Analysts assume that profit margins will shrink from 9.3% today to 8.3% in 3 years time.
- Analysts expect earnings to reach $4.2 million (and earnings per share of $0.1) by about June 2029, down from $4.5 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.6x on those 2029 earnings, up from 16.1x today. This future PE is greater than the current PE for the US IT industry at 16.1x.
- Analysts expect the number of shares outstanding to grow by 3.07% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.76%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Ongoing weakness in the transaction or DocDel business, driven by reduced spending from large corporate customers and churned accounts, could persist beyond the first half of fiscal 2026 and fail to return even to flat growth. This would limit total revenue expansion and constrain gross profit improvement.
- Intensifying competition in AI powered research tools, particularly in the B2C market where conversion from trial to paid users has already deteriorated despite product enhancements, may cap pricing power and slow new logo growth. This could pressure long term ARR growth and earnings scalability.
- If attach rates for new AI rights products like RightsDel and the Scite based AI gateway remain uncertain or materially below management’s aspirations, the expected uplift in average selling prices and high margin recurring revenue from AI monetization could fall short. This would reduce future gross margin expansion and net margin improvement.
- Publisher and enterprise adoption of AI usage tracking standards and AI licensing frameworks may progress more slowly than anticipated, delaying Research Solutions’ ability to become core AI infrastructure in the ecosystem and postponing the realization of higher margin revenue share streams. This would weigh on long term operating leverage and earnings growth.
- Sales productivity gains from recent investments in B2B sales teams and process overhauls may prove difficult to sustain across cycles, particularly if macroeconomic conditions or shifting research priorities cause further large customer budget cuts. This would increase churn risk and dampen ARR growth, cash flow generation and overall profitability.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $3.83 for Research Solutions based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $50.8 million, earnings will come to $4.2 million, and it would be trading on a PE ratio of 41.6x, assuming you use a discount rate of 8.8%.
- Given the current share price of $2.25, the analyst price target of $3.83 is 41.3% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Research Solutions?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.